Scott Michael Lieberman, M.D., F.A.C.C.

Address
115 West Fifth Street
Tyler, TX 75701

Telephone: (903) 595-2283
Fax: (903) 595-1027

Private Practice

• 1994 - Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Education

Post-doctoral Training

Fellowship

• 7/1/93-6/30/94: Interventional Cardiology Fellow, Section of Cardiology Lenox Hill Hospital, New York City
• 7/1/90-6/30/93: Cardiovascular Diseases Fellow Lenox Hill Hospital, New York City

Residency

• 1987-1990: Categorical Internal Medicine (3 Year Program) Lenox Hill Hospital, New York City Elective
• 10/89-11/89: Texas Heart Institute, Cardiovascular Service St. Luke's Hospital, Houston Texas

Medical School

• 1983-1987: New York Medical College, Valhalla, New York
• 6/1/87: Doctor of Medicine Degree

College

• 1979-1983: Wagner College, Staten Island, New York
• 5/22/83 Bachelor of Science Degree, Double Major in Chemistry and Biology

Positions Held

• 1991-1994: Adjunct Medical Attending, Department of Emergency Services, Lenox Hill Hospital, New York City
• 2/91-1994: Adjunct Medical Attending, Department of Medicine, Interventional Cardiology Care Unit, and Medicine Attending Only Floors Lenox Hill Hospital, New York City

Board Certification

• November 1993: Diplomate, American Board of Internal Medicine, Subspecialty of Cardiovascular Disease
• September 1992: Diplomate, American Board of Internal Medicine
• September 1988: Diplomate, National Board of Medical Examiners

Medical Licensure

• State of Texas
• State of New York
• Drug Enforcement Agency
• 7/91-Present: Advanced Cardiac Life Support (ACLS)
• 7/91-Present: Basic Life Support (BLS)

Hospital Appointments

• 1994-Present: Staff - Trinity Mother Frances Hospital, Tyler, Texas
• 1994-Present: Staff - East Texas Medical Center,Tyler, Texas
• 1994-Present: Consultant - East Texas Medical Center, Quitman, Texas
• 1994-Present: Consultant - East Texas Medical Center, Crockett, Texas
• 1994-Present: Consultant - East Texas Medical Center, Pittsburg, Texas
• 1994-Present: Consultant - East Texas Medical Center, Mt. Vernon, Texas
• 1994-Present: Consultant - East Texas Medical Center, Athens, Texas
• 1997-Present: Consultant - East Texas Medical Center, Jacksonville, Texas
• 1997-Present: Consultant - Laird Memorial Hospital, Kilgore, Texas
• 2000-Present: Consultant - East Texas Medical Center, Carthage, Texas
• 2001-Present: Consultant - Trinity Mother Frances Hospital, Jacksonville, Texas

Honors/Awards

• 1983: Selected to Omicron Delta Kappa, a National Leadership Honors Society
• 1983: Elected to Who's Who Among American College Seniors
• 2/85: First Place, Annual Department of Physiology Research Forum New York Medical College
• 4/2004: Texas Associated Press Managing Editors First Place for Spot News Photography

Institutional/Departmental Committee Memberships

• 1995-1998: Trinity Mother Francis Hospital & East Texas Medical Center Hospital Pharmacy and Therapeutic Committee
• 1994-Present: Member of the Research and Clinical Investigations Committee East Texas Medical Center - Tyler
• 1989-1993: Member of the Medical/Nursing Advisory Committee Lenox Hill Hospital
• 1996-Present: East Texas Medical Center peer review committee

Professional Memberships and Societies

• 1994-Present: Smith County Medical Society Texas Medical Association
• 1987-1994: Kings County Medical Society, Resident Member
• 1987-1994: Medical Society of the State of New York, Resident Member
• 1987-1994: Resident/Fellow Member of the American Medical Association
• 1988-1992: American College of Physicians, Associate Member
• 1992-Present: American College of Physicians, Member
• 1989-Present: American Heart Association
• 1994-Present: Member Board of Directors, Smith County AHA
• 1998: President, Smith County AHA
• 1990-1995: American College of Cardiology, Affiliate in Training
• 1995-Present; American College of Cardiology, Fellow
• 1991-1994: Greater New York Cardiology Fellows Association
• 1991-Present: Texas Heart Institute Cardiac Society
• 1983-Present: Phi Lambda Kappa, Brooklyn Alumni Chapter
• 1992-1994: President
• 1983-Present: Medical Student's Aid Society

Research

• Summer/Fall 1984: New York Medical College Summer Research Grant Recipient
• 1/1/91-6/30/91: Tanney Fellow in Sports Medicine and Cardiovascular Research
• 1994-1995: Co-investigator-Coumadin, Aspirin and Reinfarction Study; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients
• 1994-1995: Co-investigator-Coumadin, Aspirin and Reinfarction EKG Substudy; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
• 1996: Co-Investigator-PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion of TPA to placebo in acute MI patients with rescue angioplasty.
• 1996-2000: Co-investigator-PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.
• Co-investigator-MK-383 Protocol #008-00; A randomized, double-blind study of MK-383 in patients with unstable angina pectoris concomitantly receiving Heparin.
• 1997: Co-investigator-IMDUR (isosorbide mononitrate) P94-070 Phase IV Patient Acceptability Program. A study comparing the efficacy,safety and ease of use of three FDA-approved formulations; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit - in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use . IMDUR (isosorbide mononitrate).
• Co-investigator-BioSlide Catheter - SCIMED
• 6/91-2/93: Co-investigator & Site Coordinator - (GUSTO)-University of Michigan: Global Utilization of Streptokinase and tissue plasminogen activator for occluded coronary arteries.
• 1999-4/01: Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of ReoPro TM (ABCIXIMAB) in combination with reduced dose Retavase TM /Rapilysin TM (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
• 1991-1992: Catecholamine Levels During Exercise Testing for Arrhythmia; Relation to Venous Lactate levels.
• 1992-1995: Intra-Coronary Echocardiography (I.V.U.S.) of Native Coronaries, Bypass Grafts, and comparison to Digital Quantitative Angiography (Q.C.A.).
• 1992-1995: Intra-Coronary Ultrasound (I.V.U.S.) Comparison to Intra-Coronary Angioscopy in Coronary Interventions. A Qualitative Assessment.
• 2/99-6/99: Principal Investigator - Paragon B Trial Phase III (BC 156 86; RO 44-9883): A randomized, double-blind placebo-controlled study of Lamifiban in patients with unstable angina/non-Q wave myocardial infarction.
• 6/99-4/01: Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
• 10/99-Present: Sub- Investigator - EPHESUS - IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
• 7/1999-6/2003: Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• 7/2000- 6/2003: Co-Investigator - VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• 12/99: Principal Investigator - MICCAT ( MICardis Community Access Trial) An Phase IV - Open label evaluation of the effectivness of Micardis â ( telmisartan) on blood pressure control and quality of life in patients with essential hypertension.
• 6/99: Co-Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.
• 11/97-3/99: Co-Principal Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.
• Co-Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.
• Principal Investigator - DESTINI (Doppler Endpoint Stenting International Investigation): A multicenter randomized prospective evaluation of clinical outcome comparing primary stenting and a new practice pattern of optimal balloon angioplasty guided by quantitative angiography and intracoronary Doppler.
• Co-Investigator - NRMI - National Registry for Myocardial Infarction.
• Co-Principal Investigator - TMR012-A. A single-blind, randomized study of the safety and effectiveness of percutaneous transluminal myocardial revascularization (PTMR) performed with the Eclipse Holmium Laser as an adjunct to percutaneous coronary intervention.
• 1999-2001: Investigator - ER-TIMI 19 - A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI - the Early Retavase® (ER) - TIMI 19 Trial.
• 2000-2002: Co-Investigator - Left Main IVUS Registry - Scripps Clinic - A multicenter prospective registry designed to determine the value of diagnostic IVUS in the setting of an inconclusive coronary angiogram.
• 1/00-4/01: Co-Investigator - GUSTO IV ACS - A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ReoProT, given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation.
• 5/00-11/00: Principal Investigator - STEP AMI - An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
• 11/00-4/01: Co-Investigator - REPLACE - TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
• Co - Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
• Co-Investigator - CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease to Monitor inflammatory markers
• 8/2001-1/2004: Principal Investigator - SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS). Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532
• 5/2001-7/2002: Co-Investigator - A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone® I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US
• 8/2002-Present: Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
• 3/2002-Present: Co-Investigator - Otsuka Protocol 21-98-214-01 CASTLE " A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease."
• 9/2002-2/2004: Principal Investigator - AMIHOT - TherOx Aqueous Oxygen System - Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
• 8/2001-present: Principal Investigator - A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
• 7/2003-present: Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System
• 10/2003-present: Co-Investigator- - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST-segment elevation.

Publications

• Tolerance to Nitroglycerin in the Isolated Bovine Intra-Pulmonary Artery is Not Associated with Altered Endothelium Dependent Relaxation to Acetylcholine. Glutathione Oxidation or Modification of Guanylate Cyclase.
  Scott M. Lieberman, Jeannie M. Yu, and Michael Wolin.
  Federation Proceedings, 1985; 44#4:1234Ab.
  Presented at the National Meeting, Federated American Societies of Experimental Biology, April 1985
• International Study of Infarct Survival (ISIS) - 3 Letter to the Editor Scott M. Lieberman, Reply from Peter Slight, and Rory Collins
  Journal of the American College of Cardiology, 1991; 18#4;1147-8
• Indirect Measurements of Diastolic Blood Pressures are Elevated Compared to Direct Measurement and Factors Influencing This Relationship.
  Scott M. Lieberman, Gilbert W. Gleim, Neil L. Coplan.
  Clinical Research.
  Presented at the National Meeting, American Federation of Clinical Research, May 3, 1992.
• The Effects of a Carbohydrate-Replacement Beverage on Cardiovascular and Renal Parameters Following Exercise.
  Beth Glace, Gilbert W. Gleim, Nina Stachenfeld, Scott M. Lieberman, Ilisa Wallach, James Nicholas.
  Medicine and Science in Sports and Exercise, Abstract.
• Subacute Stent Thrombosis in Palmaz-Schatz (PS) Stents in Native Coronary Arteries: Time Course, Acute Management and Outcome. U.S. Multicenter Experience.
  Alexander Shaknovich, Krishna Rocha-Singh, Paul Teirstein, Scott M. Lieberman, Jeffery W. Moses Division of Cardiology, Lenox Hill Hospital, New York, New York
  Abstract in Circulation, October 1992.
  Presented at American Heart Association National Meeting
  November 17, 1992.
• Clinical and Angiographic Outcomes of Native Coronary Stenting With Single Palmaz-Schatz (PS) Stents.
  Update of U.S. Multicenter Experience
  Alexander Shaknovich, Scott M. Lieberman, Jeffery W. Moses.
  Section of Cardiology, Lenox Hill Hospital, New York, New York
  Journal of the American College of Cardiology, 1993;21#2A:29A
• Mechanism of Transluminal Extraction Catheter (TEC) Atherectomy in Degenerative Saphenous Vein Grafts (SVG): An Angioscopic Observational Study
  Jeffery W. Moses, Scott M. Lieberman, William Knopf, Thomas Glascock, Alexander Shaknovich, C. Undermir, Nancy Cohen.
  Lenox Hill Hospital, New York, New York; St. Joseph's Hospital, Atlanta, Georgia.
  Journal of the American College of Cardiology, 1993; 21#2A:442A
• Quantitative Angiography: Method-Dependent Bias as Function of Lumen Size
  Scott M. Lieberman, C. Undermir, G. W. Glelm, Nancy Cohen, M. S. Friedman, Alexander Shaknovich, E. M. Kreps, Jeffery W. Moses.
  Lenox Hill Hospital, New York, New York. Abstract, AHA 93.
• Coronary Flow Reserve By Doppler Wire is Not Equivalent to Stenotic Flow Reserve.
  Scott M. Lieberman, C. Undermir, Alexander Shaknovich, J. R. Wilentz, M. S. Friedman, J. Higgins, Nancy Cohen, J. McCrossan, Jeffery W. Moses.
  Lenox Hill Hospital, New York, New York. Abstract, AHA 93.